Previously CEO of EnteroBiotix, specialists in the development of microbiome modulating therapeutics, James has extensive c-suite level experience in the development and commercialisation of diagnostic and therapeutic products.
PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn's and ulcerative colitis (IBD).
Prior to EnteroBiotix James' roles included vice president of Clinical Laboratory Operations at Inivata, chief technology officer at Enterome, vice president of Research and Development at MDxHealth SA and chief operating officer at Response Genetics (IPO: NASDAQ).
This latest appointment to the PredictImmune senior team follows a wave of recent announcements including the start of a jointly sponsored study with the Crohn's and Colitis Foundation to validate PredictSURE IBD in the US market, and an announcement that PredictImmune has entered into an exclusive commercial partnership with KSL Biomedical to promote and provide PredictSURE IBD throughout North America.
Earlier in the year PredictImmune confirmed a strategic agreement with French diagnostic specialist, Theradiag, to commercialise PredictSURE IBD in France, Belgium, Luxembourg, Switzerland and the Maghreb countries.
This flurry of activity follows in the wake of the launch of PredictSURE IBD in the UK and Ireland in April this year.
Biotheus expands strategic collaboration with Hansoh Pharmaceutical Group Co
Ionis Pharmaceuticals announces positive results from phase two ION224 study
Prolytix partners with Allumiqs
10x Genomics begins shipping first two products powered by the GEM-X technology architecture
Poseida Therapeutics' P-BCMA-ALLO1 receives US FDA Orphan Drug Designation
AstraZeneca expands rare disease pipeline with Amolyt Pharma acquisition
PureTech's LYT-200 granted FDA orphan drug designation for acute myeloid leukemia treatment
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Sumitomo Pharma Canada announces ORGOVYX (relugolix) prostate cancer drug availability in Canada
Ratio Therapeutics reaches expanded manufacturing agreement with PharmaLogic